Page last updated: 2024-11-05

benzyl viologen

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Benzyl viologen, also known as 1,1'-bis(benzyl)-4,4'-bipyridinium dichloride, is a synthetic organic compound that has garnered significant attention in various fields, including electrochemistry, photochemistry, and materials science. Its synthesis typically involves the reaction of 4,4'-bipyridine with benzyl chloride in the presence of a suitable catalyst. Benzyl viologen exhibits unique electrochemical properties, particularly its ability to undergo reversible one-electron reduction, leading to the formation of a stable radical cation. This property has made it a crucial component in numerous electrochemical systems, such as redox flow batteries and electrochromic devices. Moreover, its photochemical properties have been explored for applications in solar energy conversion and photocatalysis. The presence of the benzyl groups imparts a degree of lipophilicity to the molecule, enhancing its interactions with biological membranes. This property has led to investigations of its potential biological effects, particularly its ability to act as an electron acceptor in biological redox processes. The compound's redox activity and its capacity to form stable radical cations make it a valuable tool for studying electron transfer reactions and photoinduced processes. Further research is being conducted to understand its potential applications in areas such as organic electronics, biocompatible materials, and environmental remediation.'

Benzyl Viologen: 1,1'-Bis(phenylmethyl)4,4'-bipyridinium dichloride. Oxidation-reduction indicator. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID14196
CHEMBL ID224221
CHEBI ID3056
SCHEMBL ID1108041
SCHEMBL ID13255981
MeSH IDM0002388

Synonyms (20)

Synonym
13096-46-3
benzyl viologen
C00915 ,
chebi:3056 ,
CHEMBL224221
1-benzyl-4-(1-benzylpyridin-1-ium-4-yl)pyridin-1-ium
AC1L23BQ ,
einecs 236-014-0
1,1'-bis(phenylmethyl)-4,4'-bipyridinium
4,4'-bipyridinium, 1,1'-bis(phenylmethyl)-
SCHEMBL1108041
SCHEMBL13255981
DTXSID8074493
1,1-bis(phenylmethyl)-4,4-bipyridinium
benzylviologen
1,1'-dibenzyl-[4,4'-bipyridine]-1,1'-diium
Q27105932
dibenzylviologen dication
9EC4TXL7J4
benzylviologen dication

Research Excerpts

Toxicity

ExcerptReferenceRelevance
"The role of active oxygen species and lipid peroxidation in the toxic effects of diquat, paraquat and other bipyridyl herbicides remains controversial."( Role of redox cycling and lipid peroxidation in bipyridyl herbicide cytotoxicity. Studies with a compromised isolated hepatocyte model system.
Moldeus, P; Ross, D; Sandy, MS; Smith, MT, 1986
)
0.27

Dosage Studied

ExcerptRelevanceReference
"825 mg per kg of body weight) or saline solution (controls) intraperitoneally, in single daily dosage for 15 days."( Ultrastructural alteration in the rat liver produced by benzyl viologen.
Muriana, FJ; Ruiz, V; SantamarĂ­a, C, 1987
)
0.52
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
bipyridinesCompounds containing a bipyridine group.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (7)

Assay IDTitleYearJournalArticle
AID283180Activity of PFOR in Giardia intestinalis at anaerobic condition2007Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3
Antiparasitic drug nitazoxanide inhibits the pyruvate oxidoreductases of Helicobacter pylori, selected anaerobic bacteria and parasites, and Campylobacter jejuni.
AID283182Activity of PFOR in Clostridium perfringens at anaerobic condition2007Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3
Antiparasitic drug nitazoxanide inhibits the pyruvate oxidoreductases of Helicobacter pylori, selected anaerobic bacteria and parasites, and Campylobacter jejuni.
AID283178Activity of PFOR in Trichomonas vaginalis at anaerobic condition2007Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3
Antiparasitic drug nitazoxanide inhibits the pyruvate oxidoreductases of Helicobacter pylori, selected anaerobic bacteria and parasites, and Campylobacter jejuni.
AID283184Activity of PFOR in Campylobacter jejuni at anaerobic condition2007Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3
Antiparasitic drug nitazoxanide inhibits the pyruvate oxidoreductases of Helicobacter pylori, selected anaerobic bacteria and parasites, and Campylobacter jejuni.
AID283183Activity of PFOR in Helicobacter pylori at anaerobic condition2007Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3
Antiparasitic drug nitazoxanide inhibits the pyruvate oxidoreductases of Helicobacter pylori, selected anaerobic bacteria and parasites, and Campylobacter jejuni.
AID283179Activity of PFOR in Entamoeba histolytica at anaerobic condition2007Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3
Antiparasitic drug nitazoxanide inhibits the pyruvate oxidoreductases of Helicobacter pylori, selected anaerobic bacteria and parasites, and Campylobacter jejuni.
AID283181Activity of PFOR in Clostridium difficile at anaerobic condition2007Antimicrobial agents and chemotherapy, Mar, Volume: 51, Issue:3
Antiparasitic drug nitazoxanide inhibits the pyruvate oxidoreductases of Helicobacter pylori, selected anaerobic bacteria and parasites, and Campylobacter jejuni.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (93)

TimeframeStudies, This Drug (%)All Drugs %
pre-199031 (33.33)18.7374
1990's27 (29.03)18.2507
2000's15 (16.13)29.6817
2010's18 (19.35)24.3611
2020's2 (2.15)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 31.45

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index31.45 (24.57)
Research Supply Index4.58 (2.92)
Research Growth Index4.50 (4.65)
Search Engine Demand Index38.91 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (31.45)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies1 (1.03%)4.05%
Observational0 (0.00%)0.25%
Other96 (98.97%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]